Clinical Laserthermia Systems AB (publ) publishes Annual report 2022

29 May 2023 - 20:00

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) announces today that the Company’s Annual report for 2022 has been published.

The annual report in Swedish is available on the company’s website An English version of the annual report will be published on the company’s website in June.


”CLS achieved several important milestones during 2022 and the company has primarily focused on creating good conditions for accelerated growth and commercialization through new partnerships, advancements in our clinical studies and progress within in the regulatory area. The company has also strengthened its branding and communication efforts, primarily in the American market, as part of paving the way for coming sales activity.


We now face a very exciting future and I look forward to continuing to contribute to improved treatments and increased quality of life for cancer patients and patients with neurological diseases, together with employees and shareholders,” says Dan Mogren, CEO CLS.



For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40
E-mail: [email protected]



About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: [email protected].


For more information about CLS, please visit the Company's website:


This disclosure contains information that CLS is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 29-05-2023 20:00 CET.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Clinical Laserthermia Systems AB
Clinical Laserthermia Systems develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More